Skip to main content
. 2023 Dec 11;17(1):e13690. doi: 10.1111/cts.13690

FIGURE 3.

FIGURE 3

Line plot of median (Q1–Q3) percent change from baseline in pSer166‐RIPK1 in PBMC lysates over the course of the study by dose level group – Pharmacodynamic population (a) SAD – part 1a and (b) MAD – part 2. B, baseline; BID, twice daily; D, day; MAD, multiple ascending dose; QD, once daily; pSer166‐RIPK1, phosphorylated receptor‐interacting serine/threonine protein kinase 1 at Serine 166; SAD, single ascending dose; T, time.